Appointment highlights Cardiosense’s growth trajectory following FDA clearance, clinical milestones, and expanded leadership team

Cardiosense, a digital health company pioneering AI-enabled solutions for cardiac disease management, today announced the appointment of Eric Meizlish as Chief Executive Officer (CEO). Meizlish, a seasoned healthcare technology executive with experience scaling innovative health platforms, will lead the company through its next phase of growth, succeeding co-founder Amit Gupta, who will continue as Chief Strategy Officer.

“Since co-founding the company, Amit has worked tirelessly to set the strategic vision and mission for Cardiosense, while achieving significant product and regulatory milestones, assembling a world-class team, and establishing a strong culture and foundation for continued growth,” said Jeff Trost, Managing Partner, Laerdal Million Lives Fund. “We want to thank Amit for his leadership, and we are excited to continue working together in his new role alongside Eric.”

“Eric’s appointment marks an important step in Cardiosense’s evolution as we scale our platform to democratize precision cardiac care,” said Daniel Gottlieb, Director, Broadview Ventures. “By delivering actionable insights without costly implantable sensors, the company is well-positioned to expand its impact, and Eric is the right leader to accelerate this momentum.”

Meizlish brings deep expertise in healthcare innovation and leadership, with a track record of building growth-stage companies and driving transformative partnerships. He co-founded and served as president of Lumere, a clinical evidence and analytics company acquired by Global Healthcare Exchange (GHX), where he later served as Senior Vice President of Strategy and Corporate Development. Most recently, he was CEO of Prendio-BioProcure, a leading cloud-based eProcurement platform for the life sciences industry.

“With the talent and innovation already in place at Cardiosense, we can transform how cardiac disease is managed. Our team has created a technical capability that has never existed before: the ability to accurately predict volumes and pressures within the heart, non-invasively,” said Eric Meizlish, CEO, Cardiosense. “Our next chapter is about scaling a platform that delivers these key measures to patients and providers to improve care and change the trajectory of heart disease. I look forward to working with the team to accelerate the impact for patients, providers, and partners at a moment when the industry is ready to embrace AI and digital solutions for heart health.”

This appointment further strengthens Cardiosense’s leadership bench, following the addition of John Martin, MD, as Executive Vice President and Chief Medical Officer. Over the past six months, the company has secured FDA 510(k) clearance of its CardioTag™ sensor, published breakthrough peer-reviewed results from the SEISMIC-HF I study, and advanced enrollment in its pivotal SEISMIC-HF II study.

“We started Cardiosense with the goal of changing how cardiac disease is managed by building a platform for broadly accessible, precision cardiac care,” said Amit Gupta, co-founder and newly appointed Chief Strategy Officer. “The accomplishments to date provide a strong foundation and I look forward to working with Eric, whose leadership and proven track record scaling in healthtech companies make him the right person to lead us going forward.”

About Cardiosense

Cardiosense is a digital health company pioneering AI-enabled solutions for precision cardiac care. Its platform leverages advanced biosensors and predictive analytics to enable early detection of cardiac disease and intervention, with the goal of leveraging personalized therapy to reduce hospitalizations, improve outcomes, and lower healthcare costs. Headquartered in Chicago, Cardiosense has advanced its platform with regulatory clearance and peer-reviewed clinical validation to shape the future of heart health. For more information, visit www.cardiosense.com and follow Cardiosense on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250918815054/en/

With the talent and innovation already in place at Cardiosense, we can transform how cardiac disease is managed.